(Edgar Glimpses Via Acquire Media NewsEdge) ITEM 1.01 Entry into a Material Definitive Agreement.
On May 17, 2013, Interleukin Genetics, Inc. (the "Company" or "Interleukin")
entered into a Common Stock Purchase Agreement (the "Purchase Agreement") with
various accredited investors (the "Purchasers"), pursuant to which Interleukin
sold securities to the Purchasers in a private placement transaction (the
"Private Placement"). Under the terms of the Purchase Agreement, certain
stockholders of the Company, including Pyxis Innovations, Inc. ("Pyxis") (a
wholly-owned subsidiary of Alticor, Inc.), Delta Dental Plan of Michigan, Inc.
("DDMI") and Bay City Capital Fund V, L.P. ("Bay City"), have the right to
designate representatives to the Company's Board of Directors (the "Board").
Under the Purchase Agreement, Pyxis has the right to designate two
representatives to be nominated for election to the Board, DDMI has the right to
designate one representative to be nominated for election to the Board, and Bay
City has the right to designate two representatives to be nominated for election
to the Board. On March 25, 2014, DDMI irrevocably waived its right under the
Purchase Agreement to designate a representative to be nominated for election to
the Board and to replace any such designated Board member in the event such
Board member ceases to serve as a director for any reason. Accordingly, on March
31, 2014, the Company, Pyxis, DDMI, Bay City and certain other Purchasers
entered into the First Amendment to the Purchase Agreement to delete the
provisions of the Purchase Agreement related to DDMI's right to designate a
representative to the Board. A copy of the Amendment is filed as Exhibit 10.1
hereto and incorporated by reference herein.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
(b) On March 25, 2014, Goran Jurkovic, DDMI's representative on the Board,
tendered his resignation, effective immediately, from the Board and as a member
of the Committees thereof on which he served, due to the requirements of other
(d) On March 31, 2014, Joseph M. Landstra, was elected as a Class I director to
fill the vacancy created by the previously announced resignation of James M.
Weaver to serve until the 2016 Annual Meeting of Stockholders. Mr. Landstra is
Director of Finance at Alticor Corporate Enterprises, an affiliate of Pyxis, and
was elected as the representative of Pyxis under the terms of the Purchase
Agreement (as amended). Mr. Landstra was also appointed as a member of the Audit
Committee of the Board.
In addition, on March 31, 2014, James M. Weaver, former Chairman of the Board,
was elected as a Class III director to fill the vacancy created by the
resignation of Goran Jurkovic to serve until the 2015 Annual Meeting of
Stockholders. Mr. Weaver was also re-appointed as Chairman of the Board. Mr.
Weaver formerly served as a representative of Pyxis on the Board, but is leaving
Alticor to pursue other interests. Pursuant to the terms of an Offer Letter
entered into between Mr. Weaver and the Company (the "Offer Letter"), Mr. Weaver
will receive the following compensation in consideration for his service as
Chairman of the Board:
· an annual retainer of $50,000 payable in arrears in quarterly installments of
$12,500 on the last day of each calendar quarter and prorated for any partial
· a non-qualified stock option to purchase 125,000 shares of the Company's common
stock, at an exercise price equal to the closing price of the common stock on
March 31, 2014, such option to vest as to 1/3 of the shares on the first
anniversary of the date of grant and as to 1/24 of the remaining shares at the
end of each month beginning on April 30, 2015.
A copy of the Offer Letter is filed as Exhibit 10.2 hereto and incorporated by
In addition, Mr. Weaver will be entitled to be compensated in accordance with
the Company's Director Compensation Policy as follows:
· for service as the chair of a committee, an annual retainer of $7,500;
· for service as a non-chair member of a committee, an annual retainer of $5,000;
· for each Board or committee meeting attended in person, by teleconference or by
The following is a description of arrangements that we have entered into with
Pyxis, Alticor and affiliated entities since January 1, 2012. We believe that
the transactions described below were made on terms no less favorable to us than
could have been obtained from unaffiliated third parties.
On August 17, 2006, we entered into a stock purchase agreement and further
amended the note purchase agreement with Pyxis, dated October 23, 2002, to,
among other things, provide for the establishment of a $14.3 million convertible
credit facility with Pyxis. On June 10, 2008, we drew down $4.0 million under
the convertible credit facility, leaving $10.3 million of available credit, and
issued a convertible promissory note to Pyxis in that amount. In 2009, we drew
down $3.0 million under this credit facility, leaving $7.3 million of remaining
availability. In 2010, we drew down an additional $2.0 million under the credit
facility leaving $3.3 million of remaining availability. In 2011, we drew down
an additional $2.0 million and in 2012 we drew $1.3 million of remaining
availability. There was no remaining availability to borrow under the credit
facility and the aggregate principal amount of $14,316,255, plus interest, was
due and payable in full on March 31, 2014. Pyxis had the right to convert the
principal amount into shares of common stock at a conversion price equal to
$5.68 per share, and immediately prior to the closing of the Private Placement
in May 2013, Pyxis converted all of the principal amount outstanding into
2,521,222 shares of our common stock.
On October 26, 2009, we entered into a Merchant Network and Channel Partner
Agreement with Amway Corp. d/b/a Amway Global, a subsidiary of Alticor. Pursuant
to this Agreement, Amway Global sells our Inherent Health brand of genetic tests
through its e-commerce Web site via a hyperlink to our e-commerce site. Amway
Global receives a commission equal to a percentage of net sales received by us
from Amway Global customers. The agreement has an initial term of 12 months and
is automatically renewable for successive 12-month terms. The agreement may be
terminated by either party upon 120 days written notice. As of the date of this
prospectus, we have paid Amway Global approximately $2.5 million in commissions
under this agreement, including $726,000 in 2012 and $367,000 in 2013.
Beginning in September 2012 and again in 2013, Access Business Group LLC
("ABG"), an affiliate of Alticor, placed purchase orders for our Weight
Management genetic test kits, including our processing of the tests, totaling
approximately $3.3 million. The kits are included as part of a promotional
bundle of products that Amway is now selling to their Individual Business Owners
(IBOs) pursuant to programs in 2013 and 2014. Of the $3.3 million in orders $1.8
million was received in 2013 for the 2014 program and $1.5 million for the 2013
program. The 2013 program was amended by ABG so that it would not expire at
December 31, 2013. Rather than having all program kits expire at December 31,
2013, cash received from the orders will remain in deferred revenue until the
tests are returned and processed.
On September 21, 2012, we entered into a License Agreement with Access Business
Group International LLC ("ABGI"), an affiliate of Pyxis. Pursuant to the License
Agreement, we have granted ABGI and its affiliates a non-exclusive license to
use the technology related to our Weight Management genetic test and to sell the
Weight Management test in Europe, Russia and South Africa (the "Territories").
ABGI, or a laboratory designated by ABGI or an affiliate of ABGI, will be
responsible for processing the tests, and we will receive a royalty for each
test sold, which royalty will increase if certain pending patent applications
are issued. The License Agreement has an initial term of five years from the
date of first commercial sale of the Weight Management test under the agreement.
Thereafter, the term will automatically renew for additional one-year periods
unless at least 60 days prior notice is delivered by either party. To date, we
have been paid $198,960 under this agreement, all being received in 2013.
In connection with the execution of the License Agreement, we and ABGI also
entered into a Professional Services Agreement (the "PSA") pursuant to which we
have agreed to provide services to ABGI in connection with its sale and
processing of the tests within the Territories. Services will be provided
pursuant to a statement of work to be entered into from time to time between the
parties. Such statements of work will also specify the fees to be paid by ABGI
to us for such services. The PSA has no set term and may be terminated by either
party, subject to certain conditions. As of the date of this prospectus, we have
been paid $5,250 under this agreement, all being received in 2013.
On June 29, 2012, we entered into an agreement with Pyxis to exchange the
5,000,000 shares of Series A Convertible Preferred Stock then held by Pyxis for
5,000,000 shares of newly designated Series A-1 Preferred Stock. Concurrently
therewith, we completed a financing with DDMI pursuant to which DDMI purchased
500,000 shares of Series B Preferred Stock for gross proceeds of $3,000,000. The
rights, preferences and privileges of the Series A-1 Preferred Stock and the
Series B Preferred Stock were set forth in a certificate of designations,
preferences and rights filed with the Delaware Secretary of State on June 29,
2012. Each share of Series A-1 Preferred Stock and Series B Preferred Stock was
convertible at the option of the holder into such number of fully paid and
nonassessable shares of common stock determined by dividing the applicable
original purchase price by the Series A-1 Conversion Price ($0.3196) or the
Series B Conversion Price ($0.2745), as applicable. Immediately prior to the
closing of the Private Placement: (i) Pyxis converted all 5,000,000 outstanding
shares of Series A-1 Preferred Stock into 28,160,200 shares of our common stock
and (ii) DDMI, converted all 500,000 outstanding shares of Series B Preferred
Stock into 10,928,961 shares of our common stock.
We have also entered into agreements with both Pyxis and DDMI containing certain
terms for allocating opportunities as permitted under Section 122(17) of the
Delaware General Corporation Law. These agreements regulate and define the
conduct of certain of our affairs as they may involve these stockholders and
. . .
ITEM 8.01 Other Events
On March 31, 2014, the Company issued a press release announcing the changes to
its Board as set forth above. A copy of the press release is being filed
herewith as Exhibit 99.1 and the information contained therein is incorporated
by reference into this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
Number Description of Exhibit
10.1 First Amendment, dated March 31, 2014, to Common Stock Purchase
Agreement, dated May 17, 2013.
10.2 Offer Letter, dated March 31, 2014, between Interleukin Genetics, Inc.